Watchlist
PAYS · Paysign, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Paysign’s patient-affordability expansion can sustain its August re-rating if Q3 meets revenue and program guidance and retains the full-year outlook. A weekly close below $11.50 invalidates the market thesis before that confirmation.
Kill line
A weekly close below $11.50 invalidates the August re-rating thesis. Separately, a reported active-program count at or below 160 for 2026-09-30 breaks the operating case against management’s 165–170 guidance.
Pick status
Open commitment catalyst in 10dscored if the kill line above fires How this is scored →Latest analysis and events for PAYS —
As of 13 September 2026, the latest FrontierPicks analysis for Paysign, Inc. (PAYS): Paysign’s patient-affordability expansion can sustain its August re-rating if Q3 meets revenue and program guidance and retains the full-year outlook. A weekly close below $11.50 invalidates the market thesis before that confirmation.
Kill line: A weekly close below $11.50 invalidates the August re-rating thesis. Separately, a reported active-program count at or below 160 for 2026-09-30 breaks the operating case against management’s 165–170 guidance.
Next dated event on file: — catalyst in 10d.
Current Thesis
Paysign’s patient-affordability expansion can sustain its August re-rating if third-quarter results meet the revenue and program guidance issued on 2026-08-05; a weekly close below $11.50 invalidates that market thesis. The operating test is at least $28.5 million of quarterly revenue, at least 165 active programs at 2026-09-30 and retention of the $114–117 million full-year revenue outlook. These are management’s published thresholds, not reported third-quarter results. Company earnings release.
The 2026-09-11 adjusted close of $13.01 is above the $12.53 close cited for 2026-09-02, but remains below the 2026-08-14 reference close of $13.17. Since the previous publication, a 2026-09-10 insider filing has supplied new evidence of executive selling. The price recovery alone does not establish renewed participation.
The interpretation is that the narrative is maturing — the 2026-08-05 guidance increase remains the operating anchor, while the company’s news archive checked on 2026-09-13 still ends with its 2026-08-18 conference announcement. The earlier saturation characterization was stronger than the available sentiment evidence supports: the supplied 2026-08-26 Benzinga screen is too small a sample to establish crowding. Company news archive.
Bullish and bearish views on Paysign, Inc.
The model's bull view on Paysign, Inc. (PAYS), in brief: Pharmaceutical processing leads the expansion. The bear view: Executive selling extends into September. Both cases follow in full.
Bull Case
- Pharmaceutical processing leads the expansion. Paysign’s 2026-08-05 release reported second-quarter pharmaceutical revenue of $14.65 million, up 88.9% year over year, and 148 active patient-affordability programs at 2026-06-30. Company earnings release.
- Plasma revenue withstands fewer centers. The same release reported second-quarter plasma revenue of $13.04 million, up 21.4% year over year, despite the served-center count falling by 46 to 561. Revenue growth therefore did not depend on expanding the center network during that period. Company earnings release.
Bear Case
- Executive selling extends into September. Chief Innovation Officer Michael Ngo’s Form 4, dated 2026-09-10, reports indirect sales through Gamma Innovation LLC of 70,075 shares on 2026-09-08 and 79,925 shares on 2026-09-09. Its explanatory footnotes disclose no trading plan; the transactions do not establish motive or an earnings forecast. Form 4 reproduction.
- Analyst support remains an opinion. Stock Analysis’s table, last updated 2026-09-02, lists a five-analyst average target of $13.10 and Barrington analyst Gary Prestopino’s $15 target. The 2026-09-11 reference close of $13.01 sits near that dated average; those targets provide no evidence that third-quarter programs have launched. Analyst table.
Setup & Price Structure
The supplied adjusted daily series records a 2026-09-11 close of $13.01, a three-month price increase of 86.1% and a price 8.0% below the $14.14 trailing-year high. The 14-period relative strength index was 39.4 on that date. A large preceding advance and subdued recent momentum coexist in these measurements.
The $13.17 close from 2026-08-14 remains the nearby public reference for recovery; the latest close has not reclaimed it. The $11.50 weekly-close threshold published on 2026-09-03 remains the thesis boundary, without treating it as a demonstrated support shelf. Moving-average and recent volume measurements are missing, so neither a rising-average claim nor a claim of expanding participation is supported.
Catalyst Calendar (next 30 days)
- 2026-09-30 — Third-quarter operating checkpoint. Management’s 2026-08-05 outlook specifies 165–170 active patient-affordability programs at quarter end. This is the measurement date, not an announced publication date. Company earnings release.
No third-quarter earnings announcement appears in the company archive checked on 2026-09-13. The previously cited 2026-11-04 estimate is not a confirmed earnings date: the company explicitly identifies that date as the expiration of its second-quarter telephone replay. Company archive, earnings-call notice.
What Would Change Our Mind
Failure of the retained market boundary would end the re-rating thesis: a weekly close below $11.50 is the observable price condition. Separately, a reported 2026-09-30 active-program count at or below 160 would invalidate the operating expansion case against management’s 165–170 guidance. The latter threshold remains the one published on 2026-09-03.
Evidence for the positive case requires reported third-quarter revenue of at least $28.5 million, at least 165 active programs and an unchanged or higher full-year revenue outlook before the price invalidation occurs. Until disclosure, the 2026-08-05 guidance remains a forecast rather than confirmation.
Correlation Notes
This remains a single-company setup. The 2026-08-05 segment disclosure identifies patient-affordability processing and plasma payments as the operating exposures; the supplied 2026-09-11 market snapshot contains no matched peer-return series. It cannot establish correlation with consumer-credit stocks, managed-care companies or a broader financial-sector rally.
Notes
- Micro-cap float with historical ADV near 550K shares; 15-25% single-session gaps on prints and 8-Ks are normal in this name.
- Some insider sales run under 10b5-1 plans (Newcomer's adopted 2025-09-12). Check each Form 4's plan footnote before reading a sale as discretionary.
- Coverage is five analysts. One initiation or target change moves the published average by a wide margin.
- GAAP and adjusted EPS are both reported and differ materially; the FY26 GAAP guide is $0.35-0.37. Verify which figure a headline quotes.
- Plasma customer concentration is severe: CSL, Grifols and Takeda/BioLife dominate the segment per the FY2024 10-K.
- The Q3 FY26 earnings date is estimated from prior-year cadence and has not been confirmed by the company as of 2026-09-03.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
See also · stocks to watch